Olaparib: A tale of two dosage forms

Abstract Olaparib is the first poly(ADP-ribose) polymerase (PARP) inhibitor approved by the Food and Drug Administration (FSA), with three approvals in two different cancer types. The original dosage form of olaparib was a 50 mg capsule, requiring 16 capsules per day for patients at full dose therapy which prompted development of a tablet dosage form with improved bioavailability. Herein, major trials for olaparib are reviewed and the two dosage forms are compared from a pharmacokinetic and clinical perspective.